Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Notices 104209 

Wilmington, DE; Serimmune, Goleta, 

CA; UNITED KINGDOM HEALTH 

SECURITY AGENCY (UKHSA), 

Salisbury, UNITED KINGDOM; 

University of Connecticut, Farmington, 

CT; VGXI, Inc., Conroe, TX; ABSS 

Solutions, Inc., Upper Marlboro, MD; 

BiosYnth SRL, Milan, ITALY; Idevax, 

Wijnegem, BELGIUM; IntegerBio, Inc., 

Gaithersburg, MD; Phoreus 

Biotechnology, Inc., Olathe, KS; 

PrecNA, LLC, North Potomac, MD; 

Sepragen Corp., Union City, CA; Trellis 

Bioscience, Inc., Redwood City, CA; AB 

Validation, Inc., Quebec, CANADA; 

AuraVax Therapeutics, Inc., Houston, 

TX; CuriRx, Inc., Wilmington, MA; IMA 

Evaluations, LLC, dba IMA Clinical 

Research, Tarrytown, NY; MustardSeed 

PMO, West Chester, PA; Symbiosis.io, 

LLC, Smyrna, GA; Tornado 

Therapeutics, Boston, MA; Amneal 

Pharmaceuticals of New York, LLC, 

Brookhaven, NY; Blue Spark 

Technologies, Inc., Westlake, OH; 

Inhalon Biopharma, Inc., Morrisville, 

NC; Intelligene, Inc., Taipei, TAIWAN; 

Rocket Science Health US Corp., Seattle, 

WA; Rutgers, The State University of 

New Jersey, Piscataway, NJ; The 

Administrators of the Tulane 

Educational Fund, New Orleans, LA; 

Verisim Life, Inc., San Francisco, CA; 

Arcturus Therapeutics Holdings, Inc., 

San Diego, CA; Blu Zone Bioscience & 

Supply Chain Solutions, LLC, Frederick, 

MD; Elligo Health Research, Inc., 

Austin, TX; Guide Biomedical 

Solutions, LLC, Media, PA; Integral 

Molecular, Philadelphia, PA; Komo 

Biosciences, Inc., Newton, MA; P95, BV, 

Leuven, BELGIUM; Southwest Research 

Institute, San Antonio, TX; Statistics & 

Data Corp., Tempe, AZ; Stoic Bio, Inc., 

San Diego, CA; Valaria Technical 

Consultants, LLC, Westminster, MD; 

Vaxine Pty, Ltd., Marion, AUSTRALIA; 

Zeteo Biomedical, LLC, Austin, TX; 

Concept to Market, LLC, Monrovia, MD; 

DSBio Consulting, LLC, Annapolis, MD; 

Deimos Biosciences, San Francisco, CA; 

GMED North America, Inc., Rockville, 

MD; InvisiShield Technologies, Ltd., 

Emeryville, CA; MigVax, Ltd., Kiryat 

Shmona, ISRAEL; Polaris Alpha 

Advanced Systems, Inc., 

Fredericksburg, VA; Pop Test Oncology, 

LLC, Cliffside Park, NJ; Sapphiros, 

Boston, MA; Articulate Labs, Inc., 

Dallas, TX; Empatica, Inc., Cambridge, 

MA; LifeMine Therapeutics, Inc., 

Cambridge, MA; Luminous 

Therapeutics Corp., Columbia, MD; 

Nabla Bio, Inc., Cambridge, MA; 

Qoolabs, Inc., Carlsbad, CA; Rapid 

Novor, Inc., Kitchener, CANADA; 

Scorpius BioManufacturing, San 

Antonio, TX; Sunflower Therapeutics 

PBC, Medford, MA; GreenRoads 

Diagnostics, Inc., San Diego, CA; Logical 

Images, dba ‘‘VisualDx’’, Rochester, NY; 

Mirai Biosciences, Cambridge, MA; The 

Scripps Research Institute, La Jolla, CA; 

AmplifyBio, LLC, West Jefferson, OH; 

Andelyn Biosciences, Inc., Columbus, 

OH; Binary Pharmaceuticals, LLC, Hot 

Springs, AR; BioCina PTY, Ltd., West 

Torrens, AUSTRALIA; Cypress 

Biologics, LLC, Portland, OR; Fermeate, 

Inc., San Francisco, CA; HMH Hospitals 

Corp, dba CDI, Nutley, NJ; Meso Scale 

Diagnostics, LLC, Rockville, MD; 

Systems & Technology Research, LLC, 

Woburn, MA; Telesis Bio, San Diego, 

CA; Thermo Fisher, South San 

Francisco, CA; University of 

Massachusetts Lowell, Lowell, MA; 

ViQi, Inc., Santa Barbara, CA; 

DemeTech Corp., Miami, FL; INFEX 

Therapeutics, Alderley Edge, UNITED 

KINGDOM; Mercury Bio, Inc., Santa Fe, 

NM; Phageolytix, Inc., Jacksonville, FL; 

Phenom Pharmaceuticals, LLC, Miami 

Beach, FL; RIBOPRO BV, Oss, 

NETHERLANDS; RNhale GmbH, 

Munich, GERMANY; The University of 

Chicago Medicine, Chicago, IL; Bioblue 

CMC/Manufacturing Consulting, LLC, 

San Diego, CA; Oligo Foundry, Inc., San 

Diego, CA; PNUVAX, Inc., Wilmington, 

DE; Prosoft Software, Inc., dba Prosoft 

Clinical, Chesterbrook, PA; Simon 

Williams Pharma Consulting (SWPC), 

LLC, Gibbsboro, NJ; Dillico, Meylan, 

FRANCE; INFINIFLUIDICS, 

Philadelphia, PA; Primrose Bio, Inc., 

San Diego, CA; SIMETRI, Inc., Winter 

Park, FL; The Trustees of the University 

of Pennsylvania, Philadelphia, PA; and 

WCG, Princeton, NJ, have been added as 

parties to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and RRPV intends 

to file additional written notifications 

disclosing all changes in membership. 

On January 5, 2024, RRPV filed its 

original notification pursuant to section 

6(a) of the Act. The Department of 

Justice published a notice in the Federal 

Register pursuant to section 6(b) of the 

Act on April 16, 2024 (89 FR 26928). 

The last notification was filed with 

the Department on July 11, 2024. The 

Department of Justice published a notice 

in the Federal Register pursuant to 

section 6(b) of the Act on October 11, 

2024 (89 FR 82631). 

Suzanne Morris, 

Deputy Director Civil Enforcement 

Operations, Antitrust Division. 

[FR Doc. 2024–30403 Filed 12–19–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—UHD Alliance 

Notice is hereby given that, on 

October 8, 2024, pursuant to section 6(a) 

of the National Cooperative Research 

and Production Act of 1993, 15 U.S.C. 

4301 et seq. (‘‘the Act’’), UHD Alliance, 

Inc. (‘‘UHD Alliance’’) filed written 

notifications simultaneously with the 

Attorney General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, TTE Corporation, 

Shenzhen, PEOPLE’S REPUBLIC OF 

CHINA has been added as a party to this 

venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and UHD Alliance 

intends to file additional written 

notifications disclosing all changes in 

membership. 

On June 17, 2015, UHD Alliance filed 

its original notification pursuant to 

section 6(a) of the Act. The Department 

of Justice published a notice in the 

Federal Register pursuant to section 

6(b) of the Act on July 17, 2015 (80 FR 

42537). 

The last notification was filed with 

the Department on July 8, 2024. A 

notice was published in the Federal 

Register pursuant to section 6(b) of the 

Act on September 26, 2024 (89 FR 

78904). 

Suzanne Morris, 

Deputy Director Civil Enforcement 

Operations, Antitrust Division. 

[FR Doc. 2024–30412 Filed 12–19–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Subcutaneous Drug 

Development & Delivery Consortium, 

Inc. 

Notice is hereby given that, on 

October 4, 2024, pursuant to section 6(a) 

of the National Cooperative Research 

and Production Act of 1993, 15 U.S.C. 

4301 et seq. (‘‘the Act’’), Subcutaneous 

Drug Development & Delivery 


ddrumheller on DSK120RN23PROD with NOTICES1